Analyst Thomas Shrader from BTIG maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) and keeping the price target at ...

DNLI has had a good run in the past year on positive pipeline updates. A potential approval of its Hunter Syndrome drug should be a boost. However, recent pipeline setbacks warrant caution.

William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report ...

Denali Therapeutics stock opened at $21.93 on Monday. The firm’s 50 day moving average price is $23.13 and its 200-day moving average price is $24.79. Denali Therapeutics has a 1 year low of $14 ...

Press Release Nicox Provides Business Update and Fourth Quarter 2024 Financial Highlights Last patient recruited in the NCX ...

The drugs’ active ingredient, glatiramer acetate, has been linked to more than 80 cases of anaphylaxis worldwide since ...

By linking therapeutics to engineered molecules that bind to transport receptors at the BBB, concentrations of the drugs can be increased 10- to 30-fold, according to Denali. Applying the approach ...

President Donald Trump signed an executive order Monday renaming Denali—the highest peak in North America—to Mount McKinley, the Alaska mountain’s name prior to 2015, a move he has suggested ...

The name change is likely to face some pushback in Alaska, where politicians and Alaska Natives alike have long favored calling the mountain Denali. The name, given by the Koyukon Athabascans ...

President Donald Trump says he plans to rename North America’s tallest peak, Denali in Alaska, as Mount McKinley JUNEAU, Alaska -- President Donald Trump on Monday vowed to rename North America ...

Editor’s Note: This story has been updated to correctly identify Denali. (NEXSTAR) — President Donald Trump is set to hit the ground running as he takes office for the second time on Monday.